Clinical trials: Non-Small Cell Lung Cancer (NSCLC), open to volunteers
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
This clinical trial tests how well a geriatric assessment (GA) with GA-directed treatment recommendations, compared to GA with usual care, works in identifying risk factors, reducing chemotherapy radiation toxicity and functional…
- Trial name
- NCT06139627
- Testing
- Best Practice, Biospecimen Collection, Communication Intervention
- Where
- 3 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Non-Small Cell Lung Cancer, Metastatic Lung Cancer
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
Current clinical trials testing the combination of immunotherapy with radiotherapy.
- Trial name
- REVIVE (NCT07603856)
- Testing
- Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Chicago
Non-Small Cell Lung Cancer, Melanoma (Skin Cancer)
Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
The objective of this prospective multicenter study is to evaluate whether the analysis of immunological biomarkers present in circulating extracellular vesicles is associated with the response to anti-PD-1/PD-L1 treatments in…
- Trial name
- EVpredict (NCT07376512)
- Where
- 5 sites in France
- Volunteers
- 378 people
- Sponsor
- Centre Georges Francois Leclerc
RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
This is an open-label, multicenter Phase Ib/II clinical study evaluating GFH276 in combination with tislelizumab plus pemetrexed/platinum based regimen as first-line therapy in participants with locally advanced or metastatic…
- Trial name
- GFH276X1203 (NCT07846358)
- Testing
- GFH276, with or without Tislelizumab, Pemetrexed
- Volunteers
- 84 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Non-small Cell Lung Cancer
Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
This is a prospective, pilot, single-arm, single-center study exploring the efficacy and safety of savolitinib plus docetaxel as second-line therapy in patients with MET overexpressed, EGFR/ALK/ROS1/MET ex14m-wildtype advanced…
- Trial name
- NCT05777278
- Testing
- Savolitinib, Docetaxel
- Where
- China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Non-small Cell Lung Cancer, Lung Cancer
3D Virtual Resection for Predicting Lung Function in VATS
This study aims to validate a novel preoperative assessment strategy using three-dimensional (3-D) computed tomography (CT) reconstruction and virtual resection simulation.
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, Lung Neoplasms
- Trial name
- NCT07436598
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II
Nebulized AER101 in Pre-op NSCLC
The primary objective of this pilot study is to determine if AER101 can decrease glycolysis in non-small cell lung cancer (NSCLC).
- Trial name
- AER101 (NCT07631299)
- Testing
- AER101
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- University of Oklahoma
NSCLC Stage IIIA/B, NSCLC Stage II
Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: A Multi - Omics Perspective
This research focuses on exploring biomarkers for the application of PD - 1/PD - L1 immune checkpoint inhibitors in the perioperative immunotherapy of lung cancer.
- Trial name
- NCT06856798
- Volunteers
- 120 people
- Sponsor
- Ziming Li
Urothelial Cancer, Non-small Cell Lung Cancer
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]
This clinical trial is designed to assess the safety, tolerability, and antitumor activity of Datopotamab Deruxtecan (Dato-DXd) combined with other anticancer agents or as monotherapy in participants with solid tumors.
- Trial name
- NCT07890714
- Testing
- Dato-DXd, Enfortumab Vedotin (EV), Pembrolizumab
- Where
- Taiwan
- Volunteers
- 268 people
- Sponsor
- Daiichi Sankyo
Non Small Cell Lung Cancer
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
A Single-Arm Clinical Study of Furmonertinib (160mg) Combined with Intrathecal Chemotherapy (ITC) and Stereotactic Radiotherapy (SRT) as First-Line Treatment in EGFR Classic Mutation-Positive NSCLC Patients with Brain Parenchymal…
- Trial name
- NCT07304739
- Testing
- Furmonertinib, Intrathecal chemotherapy, Stereotactic radiotherapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non Small Cell Lung Cancer
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
'1. Objective Primary objective Median Intracranial Progression-free survival(icPFS) as defined by RANO(Response Assessment in Neuro-Oncology) criteria Secondary objective Progression free survival(PFS) as defined by RECIST 1.1…
- Trial name
- ELPIS (NCT06250777)
- Testing
- Trastuzumab deruxtecan
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Yonsei University
Non-small Cell Lung Cancer
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
This study aimed to evaluate the efficacy and safety of third-generation EGFR-TKI plus anlotinib as maintenance after chemotherapy plus immunotherapy in advanced NSCLC with small cell transformation after EGFR-TKI resistance.
- Trial name
- NCT06634667
- Testing
- third-generation EGFR-TKI combined with anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Province Tumor Hospital
Non Small Cell Lung Cancer, Small-cell Lung Cancer
Phase 2 Study of Fingolimod in Lung Cancers
This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy.
- Trial name
- NCT06424067
- Testing
- Fingolimod 0.5 milligram (mg) [Gilenya]
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Medical University of South Carolina
Head and Neck Cancer, Non-Small Cell Lung Cancer
Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)
This is a Phase II clinical study for people with stage IV cancer. The study will evaluate the use of stereotactic body radiation therapy (SBRT), a type of focused radiation treatment, together with immunotherapy-based treatment.
- Conditions
- Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer
- Trial name
- NCT07770100
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mark Bernard
Non Small Cell Lung Cancer, Locally Advanced
Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
Radical radiotherapy is critical for locally advanced non small cell lung cancer(NSCLC ). Our previous sturdy indicated that patients who received induction immunotherapy and subsequent radiotherapy suffered higher proportion of…
- Conditions
- Non Small Cell Lung Cancer, Locally Advanced, Radiotherapy, Immunotherapy
- Trial name
- NCT06020430
- Testing
- CTV omitted or delineated
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Hubei Cancer Hospital
Lung Cancer (NSCLC)
Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer
In low-risk patients with stage I non-small cell lung cancer (NSCLC) surgical treatment with an anatomical resection is currently the standard of care.
- Trial name
- STRADOS (NCT07432802)
- Testing
- Stereotactic radiation therapy intervention, Surgical intervention
- Where
- 4 sites in Denmark
- Volunteers
- 182 people
- Sponsor
- Aarhus University Hospital
Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma
MOv19-BBz CAR T Cells in FRa+ Cancers
This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers.
- Trial name
- NCT07116057
- Testing
- MOv19-BBz CAR T cells, Cyclophosphamide/Fludarabine, FRa Expression Testing
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
Lung Cancer (NSCLC)
Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study investigated the efficacy and safety of Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
- Trial name
- NCT07463677
- Testing
- Tunlametinib + Cetuximab β, Tunlametinib + Fulzerasib
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer NSCLC
Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
Aim of this phase 2 study is to explore the safety and efficacy of thoracic re-irradiation +/- SBRT to oligometastases (<3) followed after an interval of 2 weeks by durvalumab and ceralasertib for patients with thoracic relapses…
- Trial name
- AUSTRAL (NCT06680050)
- Testing
- Durvalumab (MEDI4736), Ceralasertib, radiotherapy
- Where
- 9 sites in Italy, Switzerland
- Volunteers
- 21 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Radiation Esophagitis, Locally Advanced Lung Carcinoma
Esomeprazole and Radiation Induced Esophagitis
Thoracic radiation therapy combined with chemotherapy (with or without immunotherapy) is the cornerstone of management in patients with locally advanced non-small cell lung cancer (NSCLC).
- Trial name
- EERENs (NCT06120803)
- Testing
- Esomeprazole 40 mg
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Rush University Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.